A number of drugs hanging online prices open, popular large varieties to refresh the price "low line"

"
Pharmaceutical Network Industry Dynamic" Recently, Yunnan Province announced the "on the national health insurance negotiations on drug generic drug network transactionnotice." A total of 7 varieties are openly listed for online pricesOf these 7 varieties, 4 are popular large varieties, namely, Haizheng Biopharmaceutical's Adamu sing-anti, Qilu Pharmaceutical's Beval-Zhuszsa, Zhengdaqing's fennel tofatib, Shanghai's Geno Pharmaceuticals' Erlotini tabletsIt is worth noting that Qilu Pharmaceutical's Beva Zhu sing-injection liquid price reached a new low, Yunnan hanging net price of 1198 yuan / branchit is understood that the primary drug of bevalo zumas is Roche's "Anvitin", mainly used to treat a variety of malignant tumors including non-small cell lung cancer, metastatic colorectal cancer, glioma, kidney cell cancer, cervical cancer and epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancerThe indications approved in China are advanced non-small cell lung cancer and metastatic colorectal cancerthe variety is also Roche's heavyweight product, BevalZumab sales as early as 2005 broke the $1 billion mark, sales in 2019 reached 7.494 billion U.Sdollars, total sales accumulated nearly $85.9 billionAccording to Minnet.com, sales of Bevala-Zhu sing-sing-singh, a public medical institution in China, in 2019 amounted to 3.427 billion yuan, up 53.38 percent year-on-yearThe drug, which expires in Europe and the United States in 2018 and 2019, has also become a popular imitationQilu Pharmaceuticals' Bevalzhu Monoroating (commodity name "Anda") was approved for listing on December 9, 2019, and on December 14, 2019 in Shandong Province, the net price of 1266 yuan/ bottleNow half a year later, Qilu Pharmaceuticals again on the Bevalzhu mono-anti price, for 1198 yuan / branch, than the original research drug Anvirtin price is more than 700 yuan cheaperbehind its big price cuts, it's not hard to see how competitive the variety isStarting in 2019, sales revenue in China's beifl-zuma biosimilar drug market is expected to grow at a CAGR of 343.5 percent, with the market size of about 6.4 billion yuan in 2023 and 9.9 billion yuan by 2030, according to Frost Sullivanfacing a billion yuan market, in addition to Qilu Pharmaceuticals, at least 20 enterprises are competing for the first layout Since April, Green Leaf Pharmaceuticals/Boan Bio, Beida Pharmaceuticals/Haizheng Bio, Hengrui Pharmaceuticals' Shengdia Bio, and Baiota Biohave have all submitted applications for new drug listings for Bevala Zuma Biosimilar, according to the Lilac Garden Insight database In addition, Dongyu Pharmaceuticals, Hualan Gene, Fuhong Hanxuan, Shenzhou Cells, Corning Jerry, Huahai Pharmaceuticals, Tris Pharmaceuticals, Zhengda Tianqing and other enterprises of the Bevala Beads monoanti-biosimilar saucry has also entered the third phase of clinical trials industry insiders believe that, with these enterprises competing to lay out the field, the future market of biologicalsimilar drugs will continue to increase, and the first to be approved for listing of enterprises may win more market share, but pricing strategy, adaptation of continuous research and development, national collection and so on are also factors At present, the original research drug Anvitin and Zilu Pharmaceutical's Anadal have been entered the 2019 National Health Insurance Directory .　　"In health insurance, in order to gain more competitive advantage in the market, the popular varieties also have to carry out a price war, followed by the promotion of the collection, a new round of price war may also be again." Such as the above-mentioned person.